Why do DSOs trade at 14x while acquiring practices at 5x?

Add-on practices are acquired at roughly 5-8x adjusted EBITDA while the platforms acquiring them trade at 9-14x — a gap of 4-6 turns on every dollar of earnings. The mechanism is Multiple Arbitrage: DSOs buy at the small-asset multiple, bundle practices into a portfolio priced at the platform multiple, and keep the difference. Scale efficiencies (overhead leverage, supply consolidation, payer negotiations) justify part of the gap — but the arbitrage itself is a repricing of your same EBITDA.

What EBITDA improvements do DSOs make post-acquisition?

DSOs typically improve EBITDA by 20-40% through supply cost reduction (10-15%), overhead consolidation (5-10%), labor optimization (5-15%), and improved case acceptance. Practices that show these improvements early command higher acquisition multiples.

How can practice owners capture more value before selling?

Build the improvements that DSOs would make: optimize supply costs, implement systems-based overhead, train case acceptance teams, and prove recurring revenue. When you show $300K EBITDA improving to $400K, you command 6-7x instead of 5x, capturing the value yourself.

What's the difference between true EBITDA and DSO-adjusted EBITDA?

True EBITDA reflects actual operational efficiency under current ownership. DSO-adjusted EBITDA includes synergy add-backs and efficiency gains the DSO will realize. The gap is negotiable — prove which improvements you've already achieved to reduce buyer discount rates.

Should practice owners worry about the Multiple Arbitrage when exiting?

Yes, but defensively. You can't close the entire gap, but you can shrink it by improving operations pre-exit. Practices with 6.5% EBITDA margins command 6.5x multiples from DSOs, versus 5x for 4% margins. Operating excellence is your negotiating leverage.

The EBITDA Illusion: Why DSOs Buy You at 5x and Trade at 14x (And How to Keep the Difference)

Private Equity isn’t smarter than you; they just know how to format a P&L. They have mastered a financial mechanism that allows them to acquire your life’s work for a fraction of its market value, repackage it, and sell it for a fortune. This mechanism is called Multiple Arbitrage, and it’s the engine driving the consolidation of the dental industry.

This report will dissect the math, expose the mindset that makes dentists vulnerable, and provide a data-driven defense to ensure you keep the wealth you’ve created.

Section 1: The Math of Arbitrage

Multiple Arbitrage is the practice of buying smaller assets at a low multiple of their earnings, bundling them into a larger portfolio, and having that portfolio valued at a significantly higher multiple. It is the core of the DSO and private-equity playbook.

The 2025-2026 M&A market provides a stark illustration of this wealth transfer. According to the TUSK Practice Sales 2026 Dental M&A Market Report, 61% of surveyed DSOs reported that their private equity backers are expecting a moderate or high uptick in acquisition activity in 2026. The appetite is growing. And the math is brutal.

The Arbitrage Gap

Smaller “add-on” practices are being acquired for 5-8x Adjusted EBITDA. The larger “platform” buyers acquiring them trade at 9-14x EBITDA.

	Multiple	Value of the same $1M EBITDA
You sell at	5×	$5,000,000
They trade at	12×	$12,000,000
The arbitrage	+7 turns	+$7,000,000

Source: FOCUS Investment Banking, Dental Practice EBITDA Multiples; TUSK Practice Sales 2026 Dental M&A Market Report.

A private practice generating $1 million in EBITDA is acquired at 5x. The acquirer bundles it into an entity valued at 12x. The same $1 million of EBITDA is now worth $12 million on paper. Where did the extra $7 million go?

This isn’t financial wizardry. It’s a calculated, repeatable process. They are buying your practice to dress up their portfolio for the next sale. The question is: will you let them do it on their terms, or yours?

Section 2: The Villain (The “Tax-Minimization” Mindset)

For decades, the primary financial goal for most dentists has been to show the IRS as little profit as possible. Every financial decision is filtered through the lens of tax reduction. This tax-minimization mindset, while saving you pennies on your annual tax bill, costs you millions at the exit.

Buyers don’t value your practice based on its tax return. In fact, they love your tax return because it gives them ammo to drive the price down. They value you based on Adjusted EBITDA—your true cash-generating potential.

The $50,000 Mistake

The Move: You expense a $10,000 personal family vacation through the practice.

The “Win”: You save $3,700 in taxes (assuming a 37% bracket).

The Loss: You lower your EBITDA by $10,000. At a 5x multiple, you just lowered your sale price by $50,000.

You spent $50,000 to save $3,700.

You cannot optimize for Taxes and Valuation at the same time. One saves you pennies; the other costs you millions.

Section 3: The Solution (Forensic Recasting)

Adjusted EBITDA is the great equalizer. It is your reported net income with specific, justifiable expenses added back in. This process, known as recasting, transforms your tax-focused P&L into a valuation-focused one.

Consider a practice with $2 million in revenue that shows only $100,000 in net income. At a 5x multiple, this practice appears to be worth $500,000. Now, let’s apply a forensic recasting:

Line item	Amount
Reported net income	$100,000
+ Owner salary above market rate	+$150,000
+ Non-working family salaries	+$50,000
+ Personal auto & travel	+$25,000
+ One-time legal fees	+$15,000
+ Depreciation & amortization	+$20,000
+ Supply cost inefficiency (benchmarked)	+$60,000
Adjusted EBITDA	$420,000

Source: Precision Dental Analytics recasting model; add-back categories per standard QoE practice.

The same 5x multiple, applied to the recast number: $100,000 of reported income was hiding $420,000 of adjusted EBITDA. Before recasting: $500,000. After recasting: $2,100,000. Unlocked exit value: +$1,600,000 — $320,000 of recovered EBITDA × 5. That is the dollar consequence of a tax-optimized P&L walking into a valuation unprepared.

Section 4: The Defense (Data vs. Opinion)

Buyers will not simply accept your add-backs on faith. They will fight them. The TUSK report explicitly states that “differing tolerance for add-backs” is a primary reason for failed deals. This is where data becomes your shield.

Hard Add-Backs are objective. A buyer may question them, but they cannot deny them if you have the invoices (e.g., non-working family salaries or one-time legal fees).

Soft Add-Backs are where the war is won or lost.

Take the $60,000 in supply cost inefficiency from our example. A sophisticated buyer will claim that they are the ones bringing the purchasing power to fix that, so they deserve to keep the upside.

You must use data to prove that this is a “process anomaly” you have already identified and corrected, forcing them to pay for the adjusted reality. You can’t just claim your costs are high; you must prove it by benchmarking against industry data.

You cannot walk into a negotiation with opinions. You must present a data-driven case, benchmarked against the industry, that proves the true cash-generating power of your practice.

The Call to Action

The game of dental M&A is being played whether you choose to participate or not. The arbitrage gap exists because sellers are uninformed and unprepared. The buyers have the data. They have the playbook.

The only way to level the playing field is to arm yourself with the same tools.